<DOC>
	<DOCNO>NCT00264004</DOCNO>
	<brief_summary>The purpose study determine whether dos 30 mg 45 mg AZD2171 well tolerate without significant drug withdrawal accompany suitable hypertension management strategy dose reduction .</brief_summary>
	<brief_title>Study Investigate Management Hypertension Efficacy AZD2171 Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Histological cytological confirmation advance solid tumour , refractory standard therapy standard therapy exists rationale therapeutic use vascular endothelial growth factor receptor ( VEGFR ) tyrosine kinase inhibitor . Prior treatment VEGF inhibitor Poorly control hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Advanced Solid Tumours</keyword>
	<keyword>phase II</keyword>
	<keyword>Hypertension</keyword>
	<keyword>RECENTIN</keyword>
</DOC>